100 related articles for article (PubMed ID: 7193368)
21. High resolution image-cytometric differentiation of hormone sensitive and hormone insensitive prostatic carcinomas.
Schenck U; Burger G; Jütting U; Schenck UB; Wagner A; Breul J
Anal Cell Pathol; 1994 Aug; 7(2):139-52. PubMed ID: 7993824
[TBL] [Abstract][Full Text] [Related]
22. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
Labrie F; Dupont A; Cusan L; Gomez JL; Diamond P
Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
Anticancer Res; 2005; 25(5):3597-9. PubMed ID: 16101186
[TBL] [Abstract][Full Text] [Related]
25. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
26. [Hormonal, radiation and combined therapy of locally advanced prostatic cancer (T3NXM0)].
Pavlov AS; Loran OB; Simakina EP; Tomkevich BA; Repina AG; Gribova RG
Urologiia; 2005; (4):24-6. PubMed ID: 16158741
[TBL] [Abstract][Full Text] [Related]
27. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J;
Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528
[TBL] [Abstract][Full Text] [Related]
28. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
29. Estrogens in the treatment of prostate cancer.
Cox RL; Crawford ED
J Urol; 1995 Dec; 154(6):1991-8. PubMed ID: 7500443
[TBL] [Abstract][Full Text] [Related]
30. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
Robinson MR; Smith PH; Richards B; Newling DW; de Pauw M; Sylvester R
Eur Urol; 1995; 28(4):273-83. PubMed ID: 8575493
[TBL] [Abstract][Full Text] [Related]
31. Major impact of hormonal therapy in localized prostate cancer--death can already be an exception.
Labrie F; Cusan L; Gomez J; Luu-The V; Candas B; Bélanger A; Labrie C
J Steroid Biochem Mol Biol; 2004 Dec; 92(5):327-44. PubMed ID: 15698538
[TBL] [Abstract][Full Text] [Related]
32. Drug treatment of paraphilic and nonparaphilic sexual disorders.
Guay DR
Clin Ther; 2009 Jan; 31(1):1-31. PubMed ID: 19243704
[TBL] [Abstract][Full Text] [Related]
33. Adjunct bromocriptine treatment as palliation for prostate cancer: experimental and clinical evaluation.
Jacobi GH; Altwein JE; Hohenfellner R
Scand J Urol Nephrol Suppl; 1980; 55():107-12. PubMed ID: 6163204
[TBL] [Abstract][Full Text] [Related]
34. [Bromocriptine for palliation of advanced prostatic carcinoma. Experimental and clinical profile of a drug (author's' transl)].
Jacobi GH; Altwein JE
Urol Int; 1979; 34(4):266-90. PubMed ID: 89747
[TBL] [Abstract][Full Text] [Related]
35. [Studies on estrogen in human male plasma. III. Plasma peptide and steroid hormone levels in patients with prostatic cancer and renal cell carcinoma (author's transl)].
Ohashi T
Nihon Hinyokika Gakkai Zasshi; 1979 Aug; 70(8):928-40. PubMed ID: 513391
[No Abstract] [Full Text] [Related]
36. [Hyperplasia of prolactin cells after estrogen therapy in carcinoma of the prostate (author's transl)].
Hachmeister U
Verh Dtsch Ges Pathol; 1972; 56():535-9. PubMed ID: 4130889
[No Abstract] [Full Text] [Related]
37. [Hormone therapy for prostatic carcinoma and hypertrophy].
Hanschke HJ
Dtsch Med Wochenschr; 1969 Mar; 94(13):677-8. PubMed ID: 4180637
[No Abstract] [Full Text] [Related]
38. Hormone therapy in prostatic cancer.
Smith PH; Akdas A; Mason MK; Richards B; Robinson MR; de Pauw M; Sylvester R
Acta Urol Belg; 1980 Jan; 48(1):98-105. PubMed ID: 7001876
[No Abstract] [Full Text] [Related]
39. [Hormone therapy in prostatic cancer].
Marberger H; Madersbacher H
Verh Dtsch Ges Inn Med; 1967; 73():518-36. PubMed ID: 5591803
[No Abstract] [Full Text] [Related]
40. Antiandrogens in the treatment of prostatic cancer.
Bracci U
Eur Urol; 1979; 5(5):303-6. PubMed ID: 446504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
